#HAT medium

Immunological Applications

Hybridoma cells survive in HAT medium because they:

Survival in HAT environment demands functional purine and pyrimidine salvage enzymes inherited from normal B parent. B lymphocytes express HPRT1 locus on X chromosome encoding 24 kDa hypoxanthine-guanine phosphoribosyltransferase that catalyzes phosphoribosyl transfer from PRPP to hypoxanthine yielding IMP plus pyrophosphate and to guanine yielding GMP, bypassing de novo steps requiring folate. They also express cytosolic thymidine kinase 1 cell-cycle regulated peaking in S phase and mitochondrial kinase 2 constitutive, phosphorylating thymidine supplied in medium to TMP using ATP. Hybridoma c

Ref: Janeway Immunobiology salvage pathway HGPRT; Freshney Animal Cell Culture hybrids survive HAT via HGPRT TK from B cell.

View Details

Immunological Applications

Aminopterin in HAT medium functions by:

Aminopterin classifies as antifolate antimetabolite structurally analogous to folic acid with pteridine ring substitution preventing enzymatic reduction. Dihydrofolate reductase normally catalyzes NADPH dependent reduction of dihydrofolate to tetrahydrofolate, central one-carbon carrier crucial for biosynthesis. Tetrahydrofolate derivatives required at two distinct steps: 10-formyl tetrahydrofolate donates formyl groups to glycinamide ribonucleotide transformylase and aminoimidazole carboxamide ribonucleotide transformylase in de novo purine pathway synthesizing inosine monophosphate precursor

Ref: Goodman & Gilman Pharmacol 13th ed DHFR antifolate; Lodish MBoC 9th ed Fig 7-32 aminopterin blocks de novo purine thymidylate.

View Details

Immunological Applications

HAT medium contains:

HAT selective medium developed by John Littlefield in 1964 exploits metabolic auxotrophy to isolate somatic hybrids based on nucleotide salvage capability. Base medium DMEM or RPMI supplemented with fetal bovine serum provides carbon source, but three selective additives define HAT: hypoxanthine at 100 micromolar serving as purine base for salvage via hypoxanthine-guanine phosphoribosyltransferase converting to inosine monophosphate using phosphoribosyl pyrophosphate donor, thymidine at 16 micromolar supplying pyrimidine salvage substrate for thymidine kinase isoforms TK1 cytosolic and TK2 mit

Ref: Littlefield Science 1964 145:709 HAT selection; Szybalski Biochem Pharmacol HAT hypoxanthine aminopterin thymidine composition.

View Details

Immunological Applications

Myeloma cells used in hybridoma technology are selected to be:

Trastuzumab humanized IgG1 kappa mAb 148 kDa targets HER2 proto-oncogene extracellular domain IV juxtamembrane receptor overexpressed due ERBB2 amplification 17q12 20 percent breast gastric cancers poor prognosis. HER2 no known ligand but dimerizes HER1 HER2 HER3 after EGF binding autophosphorylating intracellular tyrosines Tyr1221 Tyr1222 recruiting Grb2 Shc activating PI3K Akt survival phosphorylating Bad Forkhead preventing apoptosis plus RAS RAF MEK ERK proliferation cyclin D1. Trastuzumab binds KD 5 nM sterically hindering dimerization preventing proteolytic cleavage shedding ECD generati

Ref: NEJM Trastuzumab HER2 Mechanism Slamon 2001 Clinical; FDA Herceptin Package Insert MOA Description; Janeway ADCC Trastuzumab Immune Mechanism NK Chapter 14.

View Details

Immunological Applications

Hybridoma cells survive in HAT medium because they:

Handling hybridoma cultures demands sensitive high-throughput detection secreted immunoglobulin microgram per mL among abundant serum proteins albumin bovine Ig. ELISA screening provides optimal format 96-well polystyrene plates coated purified antigen 1 ug/mL overnight 4 degrees passive hydrophobic adsorption van der Waals blocked 2 percent BSA 5 percent nonfat milk PBS preventing nonspecific binding plastic. Culture supernatant 50 uL added incubates 1h 37 degrees enabling specific binding Fab antigen interaction affinity association rate 10^5 per molar per second. After three washes PBS 0.05

Ref: Janeway Hybridoma Screening ELISA Technique Protocol; Alberts Protein A Purification Antibody Methods Chapter 8; Lodish Antibody Purification Immunotechniques Handbook Methods.

View Details

Immunological Applications

Aminopterin in HAT medium functions by:

Antibody specificity arises exquisite three-dimensional complementarity between paratope heavy light chain variable domains epitope antigen surface determining binding free energy selectivity. Variable domains each contribute three complementarity-determining regions CDR1 CDR2 CDR3 loops supported conserved framework beta sheet Ig fold creating pocket groove protruding loop accommodating antigen features charged arginine aspartate hydrophobic tryptophan phenylalanine patches hydrogen bond donors carbohydrate. Binding stabilized hydrogen bonds CDR backbone carbonyl antigen side chain salt bridg

Ref: Janeway Antibody Specificity CDR Structure Affinity Chapter 5; NCBI Antibody Antigen Recognition Principles; Alberts Immunoglobulin Variable Region Specificity Chapter 24.

View Details

Immunological Applications

HAT medium contains:

HAT medium intelligent metabolic selection exploiting two distinct pathways nucleotide biosynthesis de novo synthesis requiring tetrahydrofolate one-carbon donor and salvage reusing preformed purines pyrimidines. Aminopterin potent folic acid analog competitively inhibits dihydrofolate reductase converting dihydrofolate tetrahydrofolate Ki 0.03 nM blocking regeneration tetrahydrofolate required thymidylate synthase converting dUMP dTMP purine enzymes GAR transformylase AICAR transformylase shutting de novo purine thymidine synthesis hours. Cell survival then depends entirely salvage enzymes HP

Ref: Littlefield Science 1964 HAT Selection Classic; Janeway Immunobiology HAT Composition Components Chapter 2; Lodish Cell Culture HAT Selection Principle Media.

View Details

Basic Applied Biology

HAT medium selects hybridoma cells based on:

HAT medium selection developed by John Littlefield in 1964 exploits differential nucleotide anabolism pathways to isolate hybrid cells from mixture of parental populations. De novo purine and pyrimidine synthesis requires tetrahydrofolate-dependent enzymes, specifically aminopterin, a folate analog, competitively inhibits dihydrofolate reductase DHFR blocking de novo pathway. Alternative salvage pathway recycles hypoxanthine via hypoxanthine-guanine phosphoribosyltransferase HGPRT converting to IMP and thymidine via thymidine kinase TK to TMP, bypassing blocked de novo routes. Myeloma partners

Ref: Littlefield Science 1964 Selection of hybrids; Abbas Immunology 10th ed. HAT selection; Alberts Ch nucleotide metabolism salvage.

View Details